Literature DB >> 32512671

Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer

Özgür Önal1, Murat Koçer2, Hande Nur Eroğlu1, Servet Derya Yilmaz1, Ismet Eroğlu3, Dilek Karadoğan4.   

Abstract

Background/aim: This study aimed to investigate the effect of clinical and pathological indicators at the time of the diagnosis on overall survival in patients recently diagnosed with non-small cell lung cancer. Materials and methods: The study population consisted of patients who were diagnosed at the Faculty of Medicine at Isparta Süleyman Demirel University Hospital between January 1, 2010 and December 31, 2017 and presented to the medical oncology outpatient clinic.
Results: A total of 518 patients were evaluated, including 260 patients with squamous cell carcinoma, 207 patients with adenocarcinoma, 50 patients with non-small cell lung cancer-not otherwise specified, and 1 patient with large cell carcinoma. The average life expectancy was found to be 11.50 ± 1.40 months in patients with squamous cell carcinoma, 12.60 ± 1.59 months in patients with adenocarcinoma, and 8.70 ± 1.87 months in the other patients. The estimated 5-year relative survival rate for non-small cell lung cancer was 8% (7% for men and 18% for women). In the multivariate analysis, sex being male (HR, 2.41; P < 0.001), a performance status >2 (HR, 1.70; P < 0.001), the stage of cancer (HR, 1.37; P = 0.045), the presence of bone or liver metastasis (HR, 1.44, P = 0.009, HR, 1.57; P = 0.016, respectively), and the patient not having received radiotherapy (HR, 3.25; P < 0.001) or chemotherapy (HR, 1.85; P = 0.001) were defined as statistically significant predictive factors that reduced the overall survival. Conclusions: In this study, sex, stage, performance status, the presence of liver or bone metastases, and treatment had an effect on overall survival. This work is licensed under a Creative Commons Attribution 4.0 International License.

Entities:  

Keywords:  Non-small cell lung cancer; factors affecting survival; survival

Year:  2020        PMID: 32512671      PMCID: PMC7775717          DOI: 10.3906/sag-1912-205

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  36 in total

1.  Predictive and prognostic factors for non-small cell lung cancer--potholes in the road to the promised land.

Authors:  Adi F Gazdar; Joan H Schiller
Journal:  J Natl Cancer Inst       Date:  2011-12-08       Impact factor: 13.506

2.  Survival with inoperable lung cancer. Controlled national Veterans Administration study of radiation and chemotherapy.

Authors:  B Roswit; S Liberson; M Ohanian; H Kusik; Z Petrovich
Journal:  N Y State J Med       Date:  1976-04

3.  Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis.

Authors:  R S Pritchard; S P Anthony
Journal:  Ann Intern Med       Date:  1996-11-01       Impact factor: 25.391

4.  Specific organ metastases and survival in metastatic non-small-cell lung cancer.

Authors:  Tomohiro Tamura; Koichi Kurishima; Kensuke Nakazawa; Katsunori Kagohashi; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Mol Clin Oncol       Date:  2014-09-04

5.  Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.

Authors:  Tomoya Kawaguchi; Minoru Takada; Akihito Kubo; Akihide Matsumura; Shimao Fukai; Atsuhisa Tamura; Ryusei Saito; Yosihito Maruyama; Masaaki Kawahara; Sai-Hong Ignatius Ou
Journal:  J Thorac Oncol       Date:  2010-05       Impact factor: 15.609

6.  Controlled study of survival of patients with clinically inoperable lung cancer treated with radiation therapy.

Authors:  J Wolf; M E Patno; B Roswit; N D'Esopo
Journal:  Am J Med       Date:  1966-03       Impact factor: 4.965

7.  Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype.

Authors:  Gilda da Cunha Santos; Shui Wun Lai; Mauro Ajaj Saieg; William R Geddie; Melania Pintilie; Ming-Sound Tsao; Scott L Boerner; David Hwang
Journal:  Lung Cancer       Date:  2012-05-31       Impact factor: 5.705

8.  Pathologic fractures correlate with reduced survival in patients with malignant bone disease.

Authors:  Fred Saad; Allan Lipton; Richard Cook; Yin-Miao Chen; Matthew Smith; Robert Coleman
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

Review 9.  Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.

Authors: 
Journal:  J Clin Oncol       Date:  2008-08-04       Impact factor: 44.544

10.  Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

Authors:  R Grilli; A D Oxman; J A Julian
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544

View more
  1 in total

1.  Lung Cancer Presenting as Upper Extremity Musculoskeletal Pain: A Case Report.

Authors:  Ben Weber; Nicholas D Luke; Alyssa M Payette; Hamid Shaaban
Journal:  Cureus       Date:  2022-09-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.